Reference entry
Vesilute (ED)
ED Dipeptide · Bladder & Urinary Tract Bioregulator
Overview
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute…
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the…
Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
May support overall urinary tract function and tissue health.
Potential benefits for pelvic tissue health and function.
Mechanism
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute…
Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the…
Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
Research areas
- Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation and Gerontology. It is specifically support bladder and urinary tract function, with research indicating potential benefits for prostate health in men. Vesilute…
- Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the…
- Research explores relief of symptoms associated with bladder dysfunction through smooth muscle regulation.
- May support overall urinary tract function and tissue health.
- Potential benefits for pelvic tissue health and function.
Research notes
- Generally well-tolerated
- Injection site reactions (mild, if injectable)
- Minimal reported side effects
- Signs of allergic reaction
- Unusual urinary symptoms
Questions
Does Vesilute specifically help with prostate health or only bladder function?
Vesilute targets both bladder smooth muscle function and prostate health through blood flow and tissue regeneration. Research indicates potential for relieving BPH (benign prostatic hyperplasia) symptoms, though clinical evidence is limited. The dipeptide's small size allows penetration into prostatic tissue for…
How is Vesilute different from Prostamax or other prostate-targeting peptides?
Vesilute (ED dipeptide) is a specific Khavinson bioregulator focusing on bladder and smooth muscle regulation, while Prostamax targets prostate tissue directly. They're complementary - Vesilute works on urinary tract function; Prostamax on prostate inflammation. Combining them may provide comprehensive urogenital…
Can Vesilute improve urinary symptoms in women?
While Vesilute is studied primarily in men for prostate support, its bladder smooth muscle regulatory and microcirculation effects could theoretically benefit women with bladder dysfunction or urinary symptoms. Gender-specific research is limited, but the mechanism suggests potential for both sexes.
How long does Vesilute take to improve urinary flow or BPH symptoms?
Khavinson bioregulators typically require cycling (10-20 days on, then break) with improvements developing over 2-4 weeks during the first cycle. Maximum benefits emerge after multiple cycles (2-3 per year). Effects persist between cycles due to epigenetic changes, but bioregulator action is gradual compared to…